<DOC>
	<DOCNO>NCT00417573</DOCNO>
	<brief_summary>- This first study , aware , evaluate efficacy IgIV patient IgG subclass deficiency . - Will provide data collaboration extend study involve immunological center United States study patient similar disease .</brief_summary>
	<brief_title>Efficacy IgIv Patients With IgG Subclass Deficiency Recurrent Infections</brief_title>
	<detailed_description>*10 consent adult ( 18 old ) receive IgIV ( Gamunex 10 % ) monthly dose 400mg/kg body weight IV 3ml/minute . Comprehensive lab monitor visit , well clinical eval , plus patient complete questionnaire time . There also 3 month follow-up visit completion therapy . Specific xrays do begin last treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>IgG Deficiency</mesh_term>
	<criteria>Adult ( 18 old ) deficiency one IgG subclasses documented history recurrent infection limit upper low respiratory tract , urinary , and/or skin . Patients panhypogammaglobulinemia selective IgA deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Immunodeficiency</keyword>
	<keyword>Gammaglobulin</keyword>
	<keyword>IgG subclass deficiency recurrent infection</keyword>
</DOC>